Our History
2014
The company was established using IP from collaboration with Kary Mullis, PhD and seed investment.
2015
Laboratories at Discovery Park, Kent were established and a name change adopted. Research using Alphamer® technology started and staff numbers soon grew.
2016
Centauri established a joint venture company, Avvinity Therapeutics, with Horizon Discovery to undertake oncology research using the Alphamer® technology.
2018
Centauri was awarded an Innovate UK grant for £1.3m to undertake anti-infectives research using the Alphamer® technology
2019
Centauri was awarded a CARB-X grant for $1.4m to undertake anti-infectives research using the Alphamer® technology
2022
Centauri secured its Series A investment, moved its laboratory to Alderley Park, Cheshire and was awarded a second CARB-X grant for $2.7m to undertake anti-infectives research using the Alphamer® technology.